NMD-VCell Neuromuscular Virtual Cell Research Platform Module: Registry · Evidence → perturbation → experiment → outcome NMD = neuromuscular disorders

Release 2026.08DMD context observedDMD candidate-conditioned prediction not yet eligible

View scientific status
Evidence freeze: 3 August 2026 Resource: v1.2.0-measured-dmd-evidence Schema: 1.1 Open release status →

External-transfer benchmark

External-transfer diagnostic

55-target aggregate transfer remains unsupported

The metric adapter executes on an external aggregate-delta object. It is useful for method diagnostics but is neither cell-distribution evaluation nor a VCC submission score.

← Benchmark center

Executed now · bounded diagnostic

Multi-metric run on 55 external aggregate perturbation targets

MAE-delta, delta correlation and L1-PDS now run beside the same ridge, training-mean and zero-change predictions. The source endpoint remains NO_DIRECTIONAL_TRANSFER_SUPPORT.

AGGREGATE · NOT VCC
Target-bootstrap point estimates; lower is better for RMSE/MAE, higher is better otherwise.
MethodRMSE ΔMAE ΔPDS L1Pearson ΔSpearman ΔEffect-size ρ
Safe ridge transferdiagnostic model 1.0928 0.1861 0.5147 -0.0148 -0.0013 -0.0554
Training-response meanbaseline 1.0925 0.1844 0.5134 -0.0161 -0.0027 N/D
Zero changebaseline 1.0896 0.1707 0.5134 N/D N/D N/D

N/D means not defined. A constant or zero-variance prediction cannot support a correlation estimate. N/D is not zero and is excluded from metric comparisons.

PDS scale auditRaw prediction multiplier
0.00× 0.5134
0.25× 0.5154
0.50× 0.5164
1.00× 0.5147
2.00× 0.5144
4.00× 0.5134
8.00× 0.5193

Truth-norm matched: 0.5431 · median factor 14.52×. This uses paired observed norms and is sensitivity-only, never a fair hidden-test score.

What changed. The metric engine is operational on aggregate deltas. DES/DEG recovery and cell-distribution metrics remain locked because this prediction object has no genuine cell-level distribution.

Execution boundary. This is a formula-aligned aggregate-delta diagnostic, not an official cell-eval run, not a VCC 2025 rescore, and not a VCC 2026 task execution. No muscle, DMD, treatment or clinical validity follows from these scores.